The company is reportedly eyeing first commercial launch in the US around 2020.
Cipla is planning to deploy more funds for research and development in respiratory, dermatology, neurology and oncology segments, says report.
Report says that the company is eyeing for the first commercial launch in the US around 2020.
The company is planning a pipeline of speciality drugs in the United States, says report.
The company is planning a pipeline of speciality drugs in the United States, says report.
Cipla Ltd is currently trading at Rs. 499.75, down by Rs. 4.25 or 0.84% from its previous closing of Rs. 504 on the BSE.
The scrip opened at Rs. 505 and has touched a high and low of Rs. 505 and Rs. 499.2 respectively. So far 12837(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 40490.57 crore.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 748 on 17-Aug-2015 and a 52 week low of Rs. 495.2 on 29-Mar-2016. Last one week high and low of the scrip stood at Rs. 519 and Rs. 501.9 respectively.
The promoters holding in the company stood at 36.79 % while Institutions and Non-Institutions held 34.79 % and 26.33 % respectively.
The stock is currently trading below its 200 DMA.
No comments:
Post a Comment